Edition:
United Kingdom

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

100.00CHF
24 May 2019
Change (% chg)

-- (--)
Prev Close
CHF100.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
14,188
52-wk High
CHF141.90
52-wk Low
CHF76.10

About

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): €1,965.91
Shares Outstanding(Mil.): 15.04
Dividend: --
Yield (%): --

Financials

  COPN.S Industry Sector
P/E (TTM): -- 29.30 32.55
EPS (TTM): 0.24 -- --
ROI: 5.61 14.23 13.82
ROE: 6.12 15.46 15.25

BRIEF-Cosmo Pharmaceuticals Announces Distribution Agreement And Further Collaboration Agreement

* NEW EXCLUSIVE DISTRIBUTION AGREEMENT FOR ELEVIEW WITH MEDTRONIC IN THE US, CHINA AND SOUTH AMERICA

08 May 2019

BRIEF-Cosmo Pharmaceuticals: FDA Allowance Of IND Application For CB-03-10

* FDA Allowance Of IND Application For CB-03-10 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

07 May 2019

BRIEF-Cosmo Pharmaceuticals: Worldwide Distribution Agreement Of AI Device In Colonoscopy With Medtronic

* COSMO PHARMACEUTICALS ANNOUNCES REVOLUTIONARY ARTIFICIAL INTELLIGENCE DEVICE IN COLONOSCOPY TO DETECT LESIONS AND WORLDWIDE DISTRIBUTION AGREEMENT WITH MEDTRONIC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

10 Apr 2019

BRIEF-Cosmo Pharmaceuticals Announces Submission Of Remimazolam NDA To FDA

* ANNOUNCES SUBMISSION OF REMIMAZOLAM NDA TO FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

09 Apr 2019

BRIEF-Cosmo Pharmaceuticals FY Oper Loss Widens To EUR 16.6 Mln

* FY REVENUE EUR 65.6 MILLION COMPARED TO EUR 67.2 MILLION IN 2017

29 Mar 2019

BRIEF-Cosmo Pharmaceuticals Announces Denial Of Methylene Blue MMX Appeal

* COSMO PHARMACEUTICALS ANNOUNCES DENIAL OF METHYLENE BLUE MMX APPEAL AND BEGINNING OF ACTIVITY TO START SECOND PHASE III TRIAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

12 Mar 2019

BRIEF-Cosmo Pharmaceuticals Files Marketing Authorization Application For Methylene Blue MMX 200 Mg Tablets

* COSMO PHARMACEUTICALS FILES MARKETING AUTHORIZATION APPLICATION FOR METHYLENE BLUE MMX 200 MG TABLETS WITH EUROPEAN MEDICINES AGENCY

12 Feb 2019

BRIEF-Cosmo Pharma Files Marketing Authorization Application For Methylene Blue MMX 200 Mg Tablets With EMA

* COSMO PHARMACEUTICALS FILES MARKETING AUTHORIZATION APPLICATION FOR METHYLENE BLUE MMX 200 MG TABLETS WITH EUROPEAN MEDICINES AGENCY

12 Feb 2019

BRIEF-Cosmo Pharmaceuticals: Regulatory Update For Methylene Blue MMX

* NOW IN PROCESS OF FILING A NEW APPEAL TO OFFICE OF NEW DRUGS (OND), CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

21 Dec 2018

BRIEF-Cosmo Pharmaceuticals Launches Offering Of Senior Unsecured Convertible Bonds Due 2023

* LAUNCH OF OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS DUE 2023

28 Nov 2018

Earnings vs. Estimates

No consensus analysis data available.